Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b MAD Study of TT301/MW189 in Healthy Volunteers
NCT02942771Phase 1Completed
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MW189 in Brain Injury (BI) (5 arms). Primary endpoints: Serious Adverse Events at 4 weeks and Treatment-Emergent Adverse Events at 4 weeks. Started Mar 2017; status: completed.
02
Drugs
MW189
03
Conditions
Brain Injury (BI)
Beyond the preview
Go deeper on NCT02942771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942771.